@thetruism · 15d ago
Novartis signs $3.2 billion drug delivery deal with Alteogen
Swiss pharmaceutical giant Novartis has entered into a licensing agreement worth up to $3.2 billion with South Korea's Alteogen to utilize its subcutaneous drug delivery technology.
No further material developments are expected.
The numbers
Basel
South Korean biotech firm Alteogen.
- Novartis signed a licensing deal worth up to $3.2 billion with Alteogen.
- Novartis signed an agreement worth up to $3.2 billion with South Korean biotech firm Alteogen.
5
Sources
0
Primary
0
Corroborated
Moderate
Evidence
Where this comes from
Shared inside The Truism
No one has shared this event with commentary yet. Sharing adds context around the record — it never changes it.
Comments
Live updates
No developments recorded since this event was first published.
One living record. This page is revised as evidence arrives — it is never republished as a new article.
What we know
Developing
What we don't know
Open questions are tracked here until evidence answers them. The Truism never fills a gap with an assumption.
- Which specific therapeutics in Novartis's current pipeline will be the first to implement the Alt-B4 technology.
Update & correction history
No developments recorded since this event was first published.
The record is never silently rewritten. Every change is logged.
Loading comments…